Schonfeld Strategic Advisors LLC Sells 16,028 Shares of Akero Therapeutics, Inc. (NASDAQ:AKRO)

Schonfeld Strategic Advisors LLC trimmed its holdings in shares of Akero Therapeutics, Inc. (NASDAQ:AKRO - Free Report) by 5.8% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 262,295 shares of the company's stock after selling 16,028 shares during the period. Schonfeld Strategic Advisors LLC owned approximately 0.38% of Akero Therapeutics worth $7,297,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds have also recently bought and sold shares of the company. Sterling Capital Management LLC increased its holdings in shares of Akero Therapeutics by 764.3% in the 4th quarter. Sterling Capital Management LLC now owns 1,789 shares of the company's stock valued at $50,000 after purchasing an additional 1,582 shares during the period. Quarry LP purchased a new stake in Akero Therapeutics in the 4th quarter worth approximately $83,000. Summit Investment Advisors Inc. boosted its stake in shares of Akero Therapeutics by 6.8% during the 4th quarter. Summit Investment Advisors Inc. now owns 7,092 shares of the company's stock valued at $197,000 after buying an additional 450 shares during the period. Hsbc Holdings PLC grew its holdings in shares of Akero Therapeutics by 8.5% during the 4th quarter. Hsbc Holdings PLC now owns 7,886 shares of the company's stock valued at $220,000 after acquiring an additional 621 shares in the last quarter. Finally, AlphaQuest LLC increased its stake in shares of Akero Therapeutics by 32,588.0% in the fourth quarter. AlphaQuest LLC now owns 8,172 shares of the company's stock worth $227,000 after acquiring an additional 8,147 shares during the last quarter.

Akero Therapeutics Stock Performance

Shares of Akero Therapeutics stock traded up $0.78 on Wednesday, reaching $42.80. The stock had a trading volume of 255,168 shares, compared to its average volume of 878,280. The stock has a market cap of $3.41 billion, a P/E ratio of -11.40 and a beta of -0.12. The company has a debt-to-equity ratio of 0.05, a quick ratio of 17.25 and a current ratio of 17.25. Akero Therapeutics, Inc. has a fifty-two week low of $17.86 and a fifty-two week high of $58.40. The business's 50-day moving average price is $41.49 and its two-hundred day moving average price is $37.24.

Akero Therapeutics (NASDAQ:AKRO - Get Free Report) last posted its quarterly earnings data on Friday, February 28th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.98) by ($0.01). On average, sell-side analysts forecast that Akero Therapeutics, Inc. will post -3.99 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts have commented on the company. UBS Group boosted their target price on Akero Therapeutics from $42.00 to $109.00 and gave the company a "buy" rating in a research note on Friday, January 31st. Bank of America upgraded Akero Therapeutics from a "neutral" rating to a "buy" rating and increased their price objective for the stock from $35.00 to $63.00 in a report on Thursday, January 30th. HC Wainwright raised their price objective on shares of Akero Therapeutics from $72.00 to $75.00 and gave the company a "buy" rating in a research report on Monday, March 3rd. Canaccord Genuity Group boosted their target price on shares of Akero Therapeutics from $56.00 to $73.00 and gave the stock a "buy" rating in a research report on Tuesday, January 28th. Finally, Morgan Stanley restated an "overweight" rating on shares of Akero Therapeutics in a report on Sunday, March 2nd. Nine equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat.com, the company has a consensus rating of "Buy" and a consensus target price of $76.29.

Insider Buying and Selling at Akero Therapeutics

In related news, CEO Andrew Cheng sold 30,000 shares of the firm's stock in a transaction that occurred on Monday, February 10th. The shares were sold at an average price of $52.73, for a total value of $1,581,900.00. Following the completion of the sale, the chief executive officer now owns 686,062 shares of the company's stock, valued at $36,176,049.26. This trade represents a 4.19 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Catriona Yale sold 10,000 shares of the company's stock in a transaction on Tuesday, February 18th. The shares were sold at an average price of $49.87, for a total value of $498,700.00. Following the transaction, the insider now directly owns 95,648 shares in the company, valued at $4,769,965.76. This trade represents a 9.47 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 198,708 shares of company stock valued at $8,673,699 in the last 90 days. 7.94% of the stock is currently owned by company insiders.

Akero Therapeutics Company Profile

Akero Therapeutics, Inc, together with its subsidiary, engages in the development of treatments for patients with serious metabolic diseases in the United States. The company's lead product candidate is efruxifermin (EFX), which is in Phase 3 clinical trials that protects against cellular stress and regulates the metabolism of lipids, carbohydrates, and proteins throughout the body for the treatment of biopsy-confirmed metabolic dysfunction-associated steatohepatitis (MASH) patients.